Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 4.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.83 | 2.2 |
NAV | ₹218.14 | ₹98.38 |
Fund Started | 10 May 2005 | 25 Mar 1997 |
Fund Size | ₹8563.55 Cr | ₹1072.74 Cr |
Exit Load | For units more than 10% of the investments, an exit load of 1% if redeemed within 12 months. | Exit load of 1%, if redeemed within 30 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 19.42% | 18.64% |
3 Year | 20.53% | 23.05% |
5 Year | 23.59% | 23.70% |
1 Year
3 Year
5 Year
Equity | 97.51% | 99.31% |
Cash | 2.49% | 0.69% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
HDFC Bank Ltd. | 8.18% |
ICICI Bank Ltd. | 5.64% |
Infosys Ltd. | 4.79% |
Dixon Technologies (India) Ltd. | 3.66% |
NTPC Ltd. | 3.17% |
Bharti Airtel Ltd. | 3.08% |
Larsen & Toubro Ltd. | 2.74% |
Bharat Heavy Electricals Ltd. | 2.09% |
Reliance Industries Ltd. | 2.00% |
Vedanta Ltd. | 1.97% |
Name | Assets |
---|---|
HDFC Bank Ltd. | 7.21% |
Infosys Ltd. | 4.57% |
ICICI Bank Ltd. | 4.12% |
Dr. Reddy's Laboratories Ltd. | 3.14% |
State Bank of India | 2.74% |
NTPC Ltd. | 2.64% |
REC Ltd. | 2.49% |
Tech Mahindra Ltd. | 2.23% |
Amber Enterprises India Ltd. | 2.16% |
Suven Pharmaceuticals Ltd. | 2.07% |
Name | Akshay Sharma | Satish Ramanathan |
Start Date | 01 Dec 2022 | 01 Oct 2024 |
Name
Start Date
Description | The scheme seeks capital appreciation and/or to generate consistent returns by actively investing in equity/ equity related securities predominantly into value stocks. | The scheme aims to provide long term capital growth by investing primarily in a well-diversified portfolio of undervalued securities. |
Launch Date | 10 May 2005 | 25 Mar 1997 |
Description
Launch Date